Product
BMS-986326
3 clinical trials
4 indications
Indication
DermatitisIndication
AtopicIndication
Systemic Lupus ErythematosusIndication
Healthy ParticipantsClinical trial
A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986326 in Adult Participants With Discoid Lupus Erythematosus, Subacute Cutaneous Lupus Erythematosus, or Systemic Lupus ErythematosusStatus: Recruiting, Estimated PCD: 2025-11-24
Clinical trial
A Phase 1b, Randomized, Double-blind, Placebo-controlled, Single Dose, Crossover Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986326 at Two Dose Levels in Adult Participants With Atopic DermatitisStatus: Not yet recruiting, Estimated PCD: 2025-10-31